Testosterone does not need to bind to androgen receptors to function properly. Bicalutamide causes problems if you are castrated. evidence of cardiovascular diseases occurred only in patients who were taking Bicalutamide with leutenizing hormone receptor antagonists or GNRH analogs
Bicalutamide and cardiovascular disease Bicalutamide is currently the most frequently used antiandrogen, both alone or in combination with GnRH agonists, in order to obtain complete androgen blockade (CAB), mainly owing to the higher cardiotoxic adverse effects, observed with the use of steroidal agents. Bicalutamide was not classified in CredibleMeds (
https://www.crediblemeds.org/ index.php / login / dlcheck), an online database of drugs known to prolong QT interval and induce TdP, directly or indirectly. Data, regarding the effect of total androgen blockade (GnRH antagonist / agonist associated with androgen receptor inhibitors) in terms of rhythmic risk are lacking and need further investigation.
However, to date, several observational studies did show data, regarding the CV toxicity of bicalutamide [25, 38, 39, 51]. The results obtained from these studies demonstrated that the use of bicalutamide alone did not increase the incidence of stroke or the risk of any type of fatal and nonfatal CVD, as compared with GnRH agonist, antagonist, or orchiectomy.
These findings support the concept that alteration of systemic androgen levels may be critical for the development of CVD, whereas treatments affecting just the AR biology probably do not confer increased CVD risks. Indeed, bicalutamide does not reduce the circulating testosterone, which provides an adequate arterial compliance and metabolic regulation.
Interestingly, as previously shown, CAB was associated with an increased risk (HR 1.6 [1.3–2.0]) of hospitalizations for ischemic events (myocardial infarction or ischemic stroke), as compared with GnRH agonist alone [51], suggesting a higher CV toxicity when combining GnRH analogs with bicalutamide.